Authors ’ Reply to Sethuraman’s comment on “The Effect of Alfentanil on Emergence Delirium Following General Anesthesia in Children: A Randomized Clinical Trial”
(Source: Pediatric Drugs)
Source: Pediatric Drugs - July 29, 2022 Category: Pediatrics Source Type: research
Comment on: “The Effect of Alfentanil on Emergence Delirium Following General Anesthesia in Children: A Randomized Clinical Trial”
(Source: Pediatric Drugs)
Source: Pediatric Drugs - July 29, 2022 Category: Pediatrics Source Type: research
Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
AbstractThe pharmacokinetic and pharmacodynamic properties of the second-generation basal insulin glargine 300 Units/mL (Gla-300) may be of benefit in the treatment of type 1 diabetes mellitus (T1DM). Gla-300 provides a stable and sustained time-action profile, which is associated with glycaemic control and flexible dosing schedule. This review summarises the available evidence on the safety and efficacy of Gla-300 in children and adolescents with T1DM. Gla-300 is as effective as the first-generation basal insulin glargine 100 Units/mL (Gla-100), a standard of care for patients with diabetes in reducing HbA1c, and shows a ...
Source: Pediatric Drugs - July 26, 2022 Category: Pediatrics Source Type: research
Prevalence and Perinatal Outcomes Following In Utero Exposure to Prehospital Emergency Methoxyflurane: A 17-Year Retrospective Cohort Study
ConclusionsMethoxyflurane is commonly used by ambulance services to treat pain in pregnant women in WA. While not recommended for use in pregnancy, pregnancies exposed to methoxyflurane did not have an increased risk of adverse perinatal outcomes in this study. (Source: Pediatric Drugs)
Source: Pediatric Drugs - July 23, 2022 Category: Pediatrics Source Type: research
Outcomes of Children with Fetal and Lactation Immunosuppression Exposure Born to Female Transplant Recipients
AbstractSolid organ transplantation (SOT) is a lifesaving procedure for those with end-stage kidney, liver, heart, lung, and intestinal diseases, including females of childbearing age who wish to proceed with pregnancy following transplantation. While there is clear risk associated with use of mycophenolate during pregnancy, the risks associated with use of other immunosuppressant agents are less well understood, and the timing of use in pregnancy may be pertinent when considering the risk versus benefit for individual patients. In addition to overall fetal outcomes, including gestational age, birth weight, and mortality, ...
Source: Pediatric Drugs - July 23, 2022 Category: Pediatrics Source Type: research
Amphotericin B in Pediatrics: Analysis by Age Stratification Suggests a Greater Chance of Adverse Events from 13 Months of Age Onwards
ConclusionsClinical or observational studies based on age stratification are essential to accurately elucidate whether potentially toxic drugs can be used safely in the pediatric population. Our search for a turning point was shown to contribute to the accuracy of the study, as it provided data on the impact of D-AMB in specific pediatric age groups. (Source: Pediatric Drugs)
Source: Pediatric Drugs - July 18, 2022 Category: Pediatrics Source Type: research
Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Na ïve Children without and with Comorbidities
ConclusionLedipasvir/sofosbuvir fixed-dose combination is a safe and highly effective therapeutic option in Egyptian children aged ≥ 12 years, with chronic HCV infection, genotype 4, either without or with comorbidities. (Source: Pediatric Drugs)
Source: Pediatric Drugs - July 15, 2022 Category: Pediatrics Source Type: research
Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities
AbstractDisruptive behaviors are a class of predominantly externalizing behaviors that include physical aggression, property destruction, temper outbursts, verbal aggression, and some forms of self-injurious behaviors. Externalizing behaviors are also major components of disruptive, impulse-control and conduct disorders, disruptive mood dysregulation disorder, trauma-related and stressor-related disorders, intermittent explosive disorder, personality disorders, and other neuropsychiatric and neurodevelopmental disorders. Disruptive behaviors and associated disorders are among the most frequent reasons for child behavioral ...
Source: Pediatric Drugs - July 4, 2022 Category: Pediatrics Source Type: research
Intrapyloric Botulinum Toxin A Injection for Gastroparesis and Functional Upper Gastrointestinal Symptoms in Children: Mayo Clinic Experience, Review of the Literature, and Meta-analysis
ConclusionsIntrapyloric botulinum toxin A injection is safe in children and can offer transient relief for patients with refractory upper gastrointestinal symptoms with and without gastroparesis. (Source: Pediatric Drugs)
Source: Pediatric Drugs - June 30, 2022 Category: Pediatrics Source Type: research
Safety of Quinolones in Children: A Systematic Review and Meta-Analysis
ConclusionsAlthough the existing evidence shows that quinolone-induced musculoskeletal ADEs seem to be only short-term and reversible, and no serious skeletal and muscular system damage cases have been reported in children, quinolones should be avoided unless necessary in children because the incidence rate of quinolone-related ADEs is not low and they are broad-spectrum antibiotics that will induce the emergence of resistant strains if used frequently. (Source: Pediatric Drugs)
Source: Pediatric Drugs - June 30, 2022 Category: Pediatrics Source Type: research
Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism
AbstractAlthough rare in children, venous thromboembolism (VTE) is markedly more likely in hospitalized patients, particularly with the use of central venous access devices. Dabigatran etexilate (Pradaxa®) is one of the first direct non-vitamin K antagonist oral anticoagulants (DOAC) approved for use in pediatric patients. It is approved in the EU and USA for the treatment of VTE in patients who have been treated with a parenteral anticoagulant for ≥ 5 days, and for the prevention of recurrent VTE. In an open-label, phase 2b/3 clini cal trial in pediatric patients with acute VTE treated for ≈ 3 months, dabigat...
Source: Pediatric Drugs - June 14, 2022 Category: Pediatrics Source Type: research
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study
ConclusionA high proportion of pediatric patients with psoriasis responded to both dosing regimens of secukinumab and maintained clinical responses through 52 weeks of treatment. No clinical difference was observed in the efficacy of secukinumab across the pediatric subgroups. Safety events were consistent with the established safety profile of secuki numab.Trial RegistrationClinicalTrials.gov: NCT03668613. (Source: Pediatric Drugs)
Source: Pediatric Drugs - June 13, 2022 Category: Pediatrics Source Type: research
Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting
This article provides up-to-date information and reviews the basic principles of AD pathophysiology, diagnosis, and management. In addition, the article highlights recent advances in scientific research regarding the mechanisms involved in the pathogenesis of atopic dermatitis that have resulted in the discovery of novel therapeutic targets and the development of targeted biologic therapies with the potential to revolutionize AD therapy. (Source: Pediatric Drugs)
Source: Pediatric Drugs - June 13, 2022 Category: Pediatrics Source Type: research
The Effect of Alfentanil on Emergence Delirium Following General Anesthesia in Children: A Randomized Clinical Trial
ConclusionsIntravenous infusion of 0.2 μg/kg/min and 0.4 μg/kg/min alfentanil decreased the incidence of emergence delirium in the post-anesthesia care unit. The 0.2 μg/kg/min dose of alfentanil resulted in less respiratory depression and discharge delay than the 0.4 μg/kg/min alfentanil dose.Trial registrationChinese Clinical Trial Registry (ChiCTR2100043320) (Source: Pediatric Drugs)
Source: Pediatric Drugs - June 13, 2022 Category: Pediatrics Source Type: research
Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens –Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN
AbstractPediatric Stevens –Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threating blistering diseases triggered by medications that affect the skin and mucosae. Drug-induced epidermal necrolysis is a better term for medication-triggered cases because there is a spectrum of disease severity that otherwise is divided into the separate entities of SJS, overlap SJS/TEN, and TEN. This manuscript reviews the management of drug-induced epidermal necrolysis (DEN), including diagnosis, investigations to exclude differential diagnoses, and treatment. Diagnosis of DEN relies on clinical features and...
Source: Pediatric Drugs - June 9, 2022 Category: Pediatrics Source Type: research
